Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?
0 citations
Abstract
This Medical News article discusses the top-line results from the Lp(a)HORIZON trial, which investigated lipoprotein(a) lowering to reduce major adverse cardiovascular events.
// Source
Authors: Jennifer Abbasi